Richard Flavin
- Cancer Research top 1%
- MicroRNA in disease regulation 9
- Cancer-related molecular mechanisms research 8
- Cancer Genomics and Diagnostics 7
- Molecular Biology top 5%
- Circular RNAs in diseases 8
- Molecular Biology Techniques and Applications 6
- Oncology top 5%
- Viral-associated cancers and disorders 10
-
- Prostate Cancer Treatment and Research 7
- Otorhinolaryngology top 5%
-
- Lymphoma Diagnosis and Treatment 15
- Co-authors
- Massimo LodaOrla SheilsStéphane PelusoPaul L. NguyenStephen P. FinnJohn O’LearyPaul SmythKaren Denning
- Partner nations
- IrelandUnited StatesItaly
In The Last Decade
Richard Flavin
88 papers receiving 3.6k citations
Peers
Comparison fields: 5 of 126
- Cancer Research 1.6k
- Molecular Biology 2.0k
- Oncology 763
- Pulmonary and Respiratory Medicine 822
- Otorhinolaryngology 76
Countries citing papers authored by Richard Flavin
This map shows the geographic impact of Richard Flavin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard Flavin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard Flavin more than expected).
Fields of papers citing papers by Richard Flavin
This network shows the impact of papers produced by Richard Flavin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard Flavin. The network helps show where Richard Flavin may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Richard Flavin, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2023 | 1 | |
| 2 | 2022 | 11 | |
| 3 | 2020 | 3 | |
| 4 | 2020 | 6 | |
| 5 | 2020 | 2 | |
| 6 | 2019 | 2 | |
| 7 | 2016 | 1 | |
| 8 | Neoadjuvant crizotinib in advanced inflammatory myofibroblastic tumour with ALK gene rearrangement | 2015 | 2 |
| 9 | 2014 | 25 | |
| 10 | 2013 | 86 | |
| 11 | 2012 | 80 | |
| 12 | 2012 | 7 | |
| 13 | 2011 | 23 | |
| 14 | 2009 | 15 | |
| 15 | 2008 | 74 | |
| 16 | 2008 | 19 | |
| 17 | 2008 | 272 | |
| 18 | 2008 | 28 | |
| 19 | 2006 | 17 | |
| 20 | 2006 | 40 |
About Richard Flavin
Richard Flavin is a scholar working on Cancer Research, Pathology and Forensic Medicine and Oncology, having authored 90 papers that have together received 3.6k indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (15 papers), Viral-associated cancers and disorders (10 papers), MicroRNA in disease regulation (9 papers), Cancer-related molecular mechanisms research (8 papers), Circular RNAs in diseases (8 papers), Cancer Genomics and Diagnostics (7 papers), Prostate Cancer Treatment and Research (7 papers) and Molecular Biology Techniques and Applications (6 papers). The work is most often cited by research in Cancer Research (1.6k citations), Molecular Biology (2.0k citations) and Oncology (763 citations). Richard Flavin has collaborated with scholars based in Ireland, United States and Italy. Frequent co-authors include Massimo Loda, Orla Sheils, Stéphane Peluso, Paul L. Nguyen, Stephen P. Finn, John O’Leary, Paul Smyth, Karen Denning, Susanne Cahill and Giorgia Zadra. Their work appears in journals such as Molecular Cancer, Human Pathology, Carcinogenesis, Journal of Clinical Pathology and Modern Pathology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.